As of 2025-07-05, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -6.74. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 3,646.04 mil USD. RARE's TTM EBITDA according to its financial statements is -540.93 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.4x - 12.8x | 12.6x |
| Forward P/E multiples | 20.6x - 43.4x | 32.0x |
| Fair Price | (116.52) - (71.89) | (126.25) |
| Upside | -392.0% - -280.1% | -416.3% |
| Date | EV/EBITDA |
| 2025-07-03 | -6.74 |
| 2025-07-02 | -6.66 |
| 2025-07-01 | -6.10 |
| 2025-06-30 | -6.12 |
| 2025-06-27 | -6.15 |
| 2025-06-26 | -6.25 |
| 2025-06-25 | -6.31 |
| 2025-06-24 | -6.26 |
| 2025-06-23 | -6.20 |
| 2025-06-20 | -6.26 |
| 2025-06-18 | -6.29 |
| 2025-06-17 | -6.17 |
| 2025-06-16 | -6.25 |
| 2025-06-13 | -6.32 |
| 2025-06-12 | -6.63 |
| 2025-06-11 | -6.32 |
| 2025-06-10 | -6.32 |
| 2025-06-09 | -6.24 |
| 2025-06-06 | -6.26 |
| 2025-06-05 | -6.22 |
| 2025-06-04 | -6.16 |
| 2025-06-03 | -6.13 |
| 2025-06-02 | -6.08 |
| 2025-05-30 | -5.71 |
| 2025-05-29 | -5.89 |
| 2025-05-28 | -5.77 |
| 2025-05-27 | -5.90 |
| 2025-05-23 | -6.00 |
| 2025-05-22 | -5.97 |
| 2025-05-21 | -5.95 |
| 2025-05-20 | -6.29 |
| 2025-05-19 | -6.09 |
| 2025-05-16 | -5.99 |
| 2025-05-15 | -5.85 |
| 2025-05-14 | -5.83 |
| 2025-05-13 | -5.95 |
| 2025-05-12 | -6.07 |
| 2025-05-09 | -5.90 |
| 2025-05-08 | -6.05 |
| 2025-05-07 | -5.61 |
| 2025-05-06 | -5.89 |
| 2025-05-05 | -6.56 |
| 2025-05-02 | -6.63 |
| 2025-05-01 | -6.58 |
| 2025-04-30 | -6.58 |
| 2025-04-29 | -6.42 |
| 2025-04-28 | -6.40 |
| 2025-04-25 | -6.42 |
| 2025-04-24 | -6.34 |
| 2025-04-23 | -6.29 |